The adverse skeletal effects of selective serotonin reuptake inhibitors
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are a widely used group of antidepressants (ADs) with reported potential detrimental effects on bone mineral density (BMD) and increased fracture risk. Here, a comprehensive review of the i n vitro, in vivo and clinical studies to date was carried out using the medical search engines MEDLINE (1950 to September 2010) and EMBASE (1980 to September 2010). Serotonin (5-HT) receptors have been identified on osteoclast, osteoblast and osteocyte cell lines. The effect of SSRIs on bone formation and resorption appears to be governed by the activation of a number of 5-HT receptors on osteoblasts and osteoclasts via endocrine, autocrine/paracrine and neuronal pathways. In vitro, in vivo and clinical collective data appears to indicate that SSRIs have a negative effect on bone at the therapeutic dose levels widely used for the treatment of depression in current clinical practice. Caution may therefore have to be employed with the use of SSRIs in patients at an increased risk of falls and osteoporosis. Further studies are needed in order to fully elicit the role of SSRIs in bone formation and their effects in the low oestrogen state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin Regulates Bone Formation via the Sympathetic Nervous System
Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K. L., Armstrong, D., Ducy, P., & Karsenty, G. (2002) · Cell · doi:10.1016/s0092-8674(02)01049-8 · Cited by 1,735 · cited 1×
“Bone resorption has previously been shown to be regulated by a centrally-controlled leptin-dependent pathway acting on b2 adrenergic receptors (Adrb2) present on osteoblasts [16,20,43,45], and recent evidence has shown leptin to interfere with 5-HT production by reducing brain 5-HT synthesis and the activity of seroto…”
BackgroundLeptin regulation of bone resorption by the sympathetic nervous system and CART
Elefteriou, F., Ahn, J. D., Takeda, S., Starbuck, M., Yang, X., Liu, X., Kondo, H., Richards, W. G., Bannon, T. W., Noda, M., et al. (2005) · Nature · doi:10.1038/nature03398 · Cited by 1,311 · cited 4×
“Figure adapted from Figure adapted from [58,16].”
BackgroundInfluentialEffects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300433 · Cited by 671 · cited 1×
“Moreover, administration of 10 mg/kg/day of fluoxetine in mice resulted in similar plasma fluoxetine levels at the lower range of that found in humans taking 20–80 mg/day [15].”
BackgroundYadav, V. K., Oury, F., Suda, N., Liu, Z.-W., Gao, X.-B., Confavreux, C., Klemenhagen, K. C., Tanaka, K. F., Gingrich, J. A., Guo, X. E., et al. (2009) · Cell · doi:10.1016/j.cell.2009.06.051 · Cited by 661 · cited 6×
“It is of interest that brain-derived 5-HT has been shown to have a greater influence on bone- than gut-derived 5-HT [58] (Fig.”
BackgroundInfluentialBone Mineral Density in Women with Depression
Michelson, D., Stratakis, C., Hill, L., Reynolds, J., Galliven, E., Chrousos, G., & Gold, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351602 · Cited by 471
Diem, S. J. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1240 · Cited by 326 · cited 3×
“Clinical studies have shown a relationship between the use of SSRIs, reduced bone mineral density (BMD) and an increased risk of bone fracture [3,14,21,23,56].”
BackgroundAssociation of Low Bone Mineral Density With Selective Serotonin Reuptake Inhibitor Use by Older Men
Haney, E. M. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1246 · Cited by 286 · cited 4×
“2007 [23] Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men Cross sectional analysis of men 65+ n = 5995.”
BackgroundInfluentialBone mineral density in subjects using central nervous system-active medications
Kinjo, M., Setoguchi, S., Schneeweiss, S., & Solomon, D. H. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.07.033 · Cited by 191
Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2006) · Osteoporosis International · doi:10.1007/s00198-005-0065-y · Cited by 187 · cited 6×
“, 2006 [48], a progressive increase in the risk of fractures at the wrist, hip and spine was shown with an increasing dose of the SSRI.”
BackgroundResultInfluentialFracture Risk From Psychotropic Medications: A Population-Based Analysis
Bolton, J. M., Metge, C., Lix, L., Prior, H., Sareen, J., & Leslie, W. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817d5943 · Cited by 158
Cited by
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“The effect of SSRIs on bone formation and resorption appears to be governed by the activation of a number of 5-HT receptors on osteoblasts and osteoclasts via endocrine, autocrine/paracrine and neuronal pathways (241,253,254).”
BackgroundResultEom, C.-S., Lee, H.-K., Ye, S., Park, S. M., & Cho, K.-H. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1554 · Cited by 123
Fedotova, J., Kubatka, P., Büsselberg, D., Shleikin, A. G., Caprnda, M., Dragasek, J., Rodrigo, L., Pohanka, M., Gasparova, I., Nosal, V., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.107 · Cited by 59
Metadata
- Authors
- Tsapakis, E. M., Gamie, Z., Tran, G. T., Adshead, S., Lampard, A., Mantalaris, A., & Tsiridis, E.
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2012-04
- Volume
- 27
- Issue
- 3
- Pages
- 156-169
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W2166678842
- Cited by
- 110
- References
- 11
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The adverse skeletal effects of selective serotonin reuptake inhibitors. https://app.cochat.ai/papers/10.1016/j.eurpsy.2010.10.006
- The paper
- Tsapakis, E. M., Gamie, Z., Tran, G. T., Adshead, S., Lampard, A., Mantalaris, A., & Tsiridis, E. (2012). The adverse skeletal effects of selective serotonin reuptake inhibitors. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2010.10.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.